Kiang Wu Hospital
🇲🇴Macau S.A.R.
- Country
- 🇲🇴Macau S.A.R.
- Ownership
- -
- Established
- 1923-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.kwh.org.mo/
Everest Medicines' VELSIPITY® (Etrasimod) Gains Regulatory Traction in Greater China for Ulcerative Colitis Treatment
• Everest Medicines' VELSIPITY® (etrasimod) NDA has been accepted in Hong Kong for treating moderately to severely active ulcerative colitis in adults.
• VELSIPITY® has already been approved in Macau and implemented in the Greater Bay Area via the 'Hong Kong and Macau Medicine and Equipment Connect' policy.
• Clinical trials, including ELEVATE UC 52 and ELEVATE UC 12, support the efficacy and safety of etrasimod, showing significant clinical remission rates.
• Everest Medicines plans to submit an NDA to China's NMPA, aiming to extend the availability of this innovative therapy to more patients.
© Copyright 2025. All Rights Reserved by MedPath